AMYT - Amryt Pharma GAAP EPS of -$0.06 revenue of $61.1M reaffirms FY guidance
- Amryt Pharma press release ( NASDAQ: AMYT ): Q3 GAAP EPS of -$0.06.
- Revenue of $61.1M (+8.1% Y/Y).
- FY 2022 revenue guidance of $260M - $270M reaffirmed, representing 17-21% growth over 2021
For further details see:
Amryt Pharma GAAP EPS of -$0.06, revenue of $61.1M, reaffirms FY guidance